BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Neratinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Neratinib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04886531-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Neratinib: Phase 2 readout est. (NCT04886531)
DESCRIPTION:Neratinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Tria
 l of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-
 Positive\, HER-2 Positive Breast Cancers\nEstimated primary completion: 22
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nerat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04886531
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008275-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Neratinib: Phase 1 readout est. (NCT06008275)
DESCRIPTION:Neratinib\, phase 1\, Breast Cancer.\nStudy: Neratinib in Combi
 nation With Ruxolitinib in Patients With mTNBC\nEstimated primary completi
 on: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nerati
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06008275
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05274048-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Neratinib: Phase 1 readout est. (NCT05274048)
DESCRIPTION:Neratinib\, phase 1.\nStudy: Neratinib and Fam-Trastuzumab Deru
 xtecan in Advanced Gastro-esophageal Cancer Patients\nEstimated primary co
 mpletion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 neratinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05274048
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Neratinib: Phase 3 readout est. (NCT05615818)
DESCRIPTION:Neratinib\, phase 3.\nStudy: Personalized Medicine for Advanced
  Biliary Cancer Patients\nEstimated primary completion: June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/neratinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05388149-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Neratinib: Phase 2 readout est. (NCT05388149)
DESCRIPTION:Neratinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Kadc
 yla And Neratinib for Interception of HER2+ Breast Cancer With Molecular R
 esidual Disease\nEstimated primary completion: July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/neratinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05388149
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02932280-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Neratinib: Phase 1/2 readout est. (NCT02932280)
DESCRIPTION:Neratinib\, phase 1/2.\nStudy: Safety and Dose Finding Study of
  Neratinib in Children and Young Adults With Cancer That Has Returned or N
 ot Responded to Treatment\nEstimated primary completion: October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/neratinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT02932280
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07333937-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:Neratinib: Phase 2 readout est. (NCT07333937)
DESCRIPTION:Neratinib\, phase 2\, Breast Cancer.\nStudy: Neratinib Combined
  With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breas
 t Cancer\nEstimated primary completion: 20 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/neratinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07333937
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02977780-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Neratinib: Phase 2 readout est. (NCT02977780)
DESCRIPTION:Neratinib\, phase 2.\nStudy: INdividualized Screening Trial of 
 Innovative Glioblastoma Therapy (INSIGhT)\nEstimated primary completion: 1
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nerat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T02977780
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05760612-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Neratinib: Phase 3 readout est. (NCT05760612)
DESCRIPTION:Neratinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Adju
 vant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epiderm
 al Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trast
 uzumab Plus Pertuzumab\nEstimated primary completion: 16 February 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/neratinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05760612
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813079-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:Neratinib: Phase 2 readout est. (NCT06813079)
DESCRIPTION:Neratinib\, phase 2.\nStudy: Using Tumor Models to Determine Tr
 eatments\nEstimated primary completion: 17 February 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/neratinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06813079
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109467-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Neratinib: Phase 2 readout est. (NCT06109467)
DESCRIPTION:Neratinib\, phase 2.\nStudy: Neratinib In Combination With Chem
 otherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer\nEstima
 ted primary completion: March 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/neratinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06109467
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05372614-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20280717
DTEND;VALUE=DATE:20280718
SUMMARY:Neratinib: Phase 1 readout est. (NCT05372614)
DESCRIPTION:Neratinib\, phase 1.\nStudy: Testing the Safety and Tolerabilit
 y of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancer
 s With Changes in the HER2 Gene\nEstimated primary completion: 17 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/neratinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05372614
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152782-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Neratinib: Phase 2 readout est. (NCT07152782)
DESCRIPTION:Neratinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: T-DX
 d With or Without Neratinib for HER2 Positive Breast Cancer With Brain Met
 astasis\nEstimated primary completion: August 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/neratinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07152782
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04374305-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Neratinib: Phase 2 readout est. (NCT04374305)
DESCRIPTION:Neratinib\, phase 2.\nStudy: Innovative Trial for Understanding
  the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-
 NF2)\nEstimated primary completion: 1 December 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/neratinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04374305
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933395-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Neratinib: Phase 2 readout est. (NCT05933395)
DESCRIPTION:Neratinib\, phase 2\, Breast Cancer.\nStudy: Genetically-inform
 ed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor\nEstimated primary 
 completion: October 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/neratinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05933395
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Neratinib: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Neratinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: I-SP
 Y TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breas
 t Cancer\nEstimated primary completion: December 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/neratinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729046-2258@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Neratinib: Phase 2 readout est. (NCT07729046)
DESCRIPTION:Neratinib\, phase 2\, Breast Cancer.\nStudy: Neu Direction: Tes
 ting the Efficacy of Adding HER Inhibition to Standard of Care in Metastat
 ic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer\nEstimated primary
  completion: May 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/neratinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07729046
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
